文献速递消化道肿瘤放疗胸部肿瘤放疗

肺静脉亚结构放疗剂量与食管鳞癌新辅助放化疗后房颤的关联

Association between radiation dose to pulmonary vein substructures and post-treatment atrial fibrillation following neoadjuvant chemoradiotherapy for esophageal squamous cell cancer.
PubMed 文献 · Radiother Oncol · 2026-02-08

该回顾性分析纳入209例接受新辅助放化疗的食管鳞癌患者,勾画肺静脉亚结构并提取剂量体积参数,系统监测房颤事件。多因素竞争风险回归显示左侧下肺静脉最大剂量是房颤的独立预测因子,且房颤与更差的2年无复发生存和总生存相关。

要点

  • 左侧下肺静脉最大剂量是食管鳞癌新辅助放化疗后房颤的独立预测因子。
  • 左侧下肺静脉最大剂量>28.87 Gy者房颤发生率显著更高(12.3%)。
  • 发生房颤者2年无复发生存和总生存均更差。

核心结论

  • 左侧下肺静脉最大剂量与食管鳞癌新辅助放化疗后房颤风险增加独立相关,并与更差的生存结局相关。

研究设计与样本

  • 回顾性分析纳入209例接受新辅助放化疗的食管鳞癌患者,在放疗计划扫描上勾画肺静脉亚结构并提取剂量体积直方图参数,通过系统心脏监测确认房颤事件,采用多因素竞争风险回归分析,调整心血管危险因素、手术切除作为时依协变量及死亡作为竞争风险。

主要发现

  • 209例患者中男性占84.9%,中位年龄66岁,2年房颤累积发生率为8.89%,房颤中位时间为13个月。
  • 25例房颤事件中15例(60%)发生于食管切除术后,手术至房颤的中位时间为2.1个月。
  • 单因素分析中年龄、高血压、左侧下肺静脉最大剂量、右侧上肺静脉最大剂量和冠心病与房颤相关。
  • 多因素模型中左侧下肺静脉最大剂量仍为独立预测因子(调整HR=3.16,95%CI:1.19-8.42,p=0.021),年龄(HR=3.66,p=0.009)和冠心病(HR=2.59,p=0.019)亦显著。
  • 左侧下肺静脉最大剂量>28.87 Gy者房颤发生率(12.3%)显著高于低于该阈值者(p=0.008);房颤与更差的2年无复发生存(36.9% vs. 78.6%,p=0.0051)和2年总生存(58.3% vs. 82.1%,p=0.012)相关。

关键数值与推荐

  • 左侧下肺静脉最大剂量>28.87 Gy与房颤发生率12.3%相关(p=0.008)。
  • 多因素模型中左侧下肺静脉最大剂量调整HR=3.16(95%CI:1.19-8.42,p=0.021)。

临床怎么用

  • 结果提示左侧下肺静脉保护性放疗技术可能具有潜在价值,并需在该人群中加强房颤监测。
  • 在建立明确临床指南前,需在更大前瞻性队列中进行外部验证。

局限性

  • 原文为回顾性分析,结论需在更大前瞻性队列中外部验证后才能建立明确临床指南。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To determine whether incidental radiation dose to pulmonary vein (PV) substructures---known arrhythmogenic sites---was associated with increased risk of atrial fibrillation (AF) in patients with esophageal squamous cell carcinoma (ESCC) undergoing neoadjuvant chemoradiotherapy (nCRT). METHODS: We conducted a retrospective analysis of 209 ESCC patients treated with nCRT. PV substructures (LSPV, LIPV, RSPV, RIPV) were contoured on radiotherapy planning scans, and dose-volume histogram parameters were extracted. AF events were ascertained through systematic cardiac monitoring. Multivariate competing risk regression was employed to assess associations between PV doses and AF, with adjustment for cardiovascular risk factors, surgical resection as a time-dependent covariate, and mortality as a competing risk. RESULTS: Among 209 patients (84.9% male; median age 66 years), the 2-year cumulative incidence of AF was 8.89%, with a median time to AF of 13 months. Among the 25 AF events, 15 (60%) occurred after esophagectomy, with a median time from surgery to AF of 2.1 months. On univariate analysis, age, hypertension, LIPV-∼Dmax∼, RSPV-∼Dmax∼, and coronary heart disease (CHD) were associated with AF. In the multivariable model, LIPV-∼Dmax remained an independent predictor (adjusted HR = 3.16, 95% CI: 1.19-8.42, p = 0.021) after adjustment for age (HR = 3.66, p = 0.009), CHD (HR = 2.59, p = 0.019), and surgical resection. Patients with LIPV-∼Dmax∼ >28.87 Gy had a significantly higher AF incidence (12.3%) than those below this threshold (p = 0.008). Moreover, AF was associated with inferior 2-year recurrence-free survival (36.9% vs. 78.6%, p = 0.0051) and inferior 2-year overall survival (58.3% vs. 82.1%, p = 0.012). CONCLUSION: Maximum dose to the LIPV was independently associated with increased AF risk and worse survival outcomes in ESCC patients receiving nCRT. These results highlighted the potential value of LIPV-sparing radiotherapy techniques and enhanced AF surveillance in this population. External validation in larger prospective cohorts was needed before firm clinical guidelines can be established.

来源:Radiother Oncol,查看原文。版权归原作者所有。

引用

  1. Huang Z, Qi WX, Li S, et al. Association between radiation dose to pulmonary vein substructures and post-treatment atrial fibrillation following neoadjuvant chemoradiotherapy for esophageal squamous cell cancer. Radiother Oncol. 2026. PMID: 41667012. doi:10.1016/j.radonc.2026.111436

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。